TY - JOUR
T1 - Riociguat treatment for portopulmonary hypertension
T2 - a subgroup analysis from the PATENT-1/-2 studies
AU - Cartin-Ceba, Rodrigo
AU - Halank, Michael
AU - Ghofrani, Hossein Ardeschir
AU - Humbert, Marc
AU - Mattson, John
AU - Fritsch, Arno
AU - Krowka, Michael
N1 - Funding Information:
Medical writing assistance was provided by Adelphi Communications Ltd (Bollington, UK), funded by Bayer AG (Berlin, Germany).
Publisher Copyright:
© 2018, The Author(s) 2018.
PY - 2018/4/1
Y1 - 2018/4/1
N2 - In patients with portopulmonary hypertension (n = 13) included in the 12-week randomized placebo-controlled PATENT-1 trial, riociguat was well tolerated and improved 6-min walking distance (6MWD), World Health Organization functional class (WHO FC), and other efficacy parameters; 6MWD and WHO FC improvements were sustained over two years in the open-label extension, PATENT-2.
AB - In patients with portopulmonary hypertension (n = 13) included in the 12-week randomized placebo-controlled PATENT-1 trial, riociguat was well tolerated and improved 6-min walking distance (6MWD), World Health Organization functional class (WHO FC), and other efficacy parameters; 6MWD and WHO FC improvements were sustained over two years in the open-label extension, PATENT-2.
KW - portal hypertension
KW - pulmonary arterial hypertension
KW - soluble guanylate cyclase stimulator
UR - http://www.scopus.com/inward/record.url?scp=85049873206&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85049873206&partnerID=8YFLogxK
U2 - 10.1177/2045894018769305
DO - 10.1177/2045894018769305
M3 - Letter
AN - SCOPUS:85049873206
VL - 8
JO - Pulmonary Circulation
JF - Pulmonary Circulation
SN - 2045-8932
IS - 2
ER -